Search Results
Your search for ,loW matches 7101 pages
Showing 2601 - 2650Comanagement of Induction Therapy for Acute Promyelocytic Leukemia by Experts and Community Practices
In a study reported in JCO Oncology Practice, Anand P. Jillella, MD, and colleagues found that physician education on the main causes of death during induction treatment for acute promyelocytic leukemia (APL)—and comanagement of cases with expert physicians—resulted in a low early mortality rate...
James L. Mulshine, MD, on Meeting Highlights: Advancing Quantitative Low-Dose CT Imaging in Thoracic Disease
James L. Mulshine, MD, of Rush University Medical Center, offers an overview of the 2020 Quantitative Imaging Workshop, whose mission is to leverage the use of CT to speed early detection and improve the management of lung cancer and other thoracic diseases.
Hospital Outpatient Payment Proposal Has Potential to Undermine Patient Access to Cancer Care
In a comment letter to the Centers for Medicare & Medicaid Services (CMS), the Association for Clinical Oncology (ASCO) expressed significant concerns that provisions in the 2021 Hospital Outpatient Prospective Payment System (HOPPS) proposed rule have the potential to undermine access to...
COVID-19’s Impact on Cancer Care Around the World: Perspectives From the ASCO International Affairs Committee
As the world continues to respond to the COVID-19 pandemic, ASCO is committed to providing the most current information and resources to its members and the larger oncology community to help ensure that patients with cancer receive high-quality care. Here, members of the ASCO International Affairs...
DANUBE Trial Reports No Survival Benefit With First-Line Durvalumab in Metastatic Urothelial Carcinoma
As reported in The Lancet Oncology by Thomas Powles, MD, of Barts Cancer Institute, Queen Mary University of London, and colleagues, the phase III DANUBE trial showed that durvalumab monotherapy did not prolong overall survival vs standard chemotherapy in previously untreated patients with...
Predicting Cardiovascular Disease Risk Via Routine CT Scans in Women With Breast Cancer
Coronary artery calcification scores based on routine computed tomography (CT) scans used for planning radiotherapy therapy may be able to predict which women with breast cancer have a high probability of developing cardiovascular disease. The promise of this research is that once high-risk...
As a Young Oncologist, Enrique Soto Pérez de Celis, MD, MSc, Met a Career-Changing Mentor at the ASCO Annual Meeting
Geriatric oncologist and researcher Enrique Soto Pérez de Celis, MD, MSc, was born in Mexico City and grew up in the nearby city of Puebla. “There were no physicians in the family who might have influenced my decision to become a doctor, but both of my parents were academics; my mother was a...
Expert Point of View: Sonali M. Smith, MD, FASCO
Sonali M. Smith, MD, FASCO, the Elwood V. Jensen Professor in Medicine, Interim Chief of Hematology/Oncology, and Director of the Lymphoma Program at the University of Chicago Medical Center, told The ASCO Post that communication between the patient and the caregiving team has become increasingly...
Reducing Emergency Department Visits: Better Patient Outreach May Improve Care, Treatment Costs
Identifying patients at risk for adverse outcomes and intervening with intensive clinical services may improve cancer care while saving billions of dollars in avoidable emergency department (ED) visits. And, in fact, cancer centers may already have all the information they need to do so, according...
Fragment Analysis as a MET Exon 14 Screening Strategy in NSCLC Tumors
Comparison of two techniques used in screening non–small cell lung cancer (NSCLC) tumor samples demonstrated that fragment analysis could detect large MET exon 14 skipping deletions that were missed by next-generation sequencing, according to findings presented at the Molecular Analysis for...
Do All Patients With Refractory Diffuse Large B-Cell Lymphoma Need CAR T-Cell Therapy?
Chimeric antigen receptor (CAR) T-cell therapy has made great strides in treating patients with relapsed or refractory diffuse large-B cell lymphoma (DLBCL) and refractory mantle cell lymphoma (MCL), but there may be newer strategies that can produce equivalent outcomes, and not all patients with...
No Biochemical Progression-Free Survival Benefit With Adjuvant vs Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer
As reported in The Lancet by Christopher C. Parker, MD, of Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, and colleagues, initial findings in the phase III RADICALS-RT trial have shown no biochemical progression-free survival benefit with adjuvant radiotherapy vs a policy of salvage...
Expert Point of View: Tim Price, MBBS, DHthSc
The invited discussant of PRODIGE 13 was Tim Price, MBBS, DHthSc, Professor at the University of Adelaide, Australia, senior consultant medical oncologist, and Director of Medical Oncology and Clinical Cancer Research at the Queen Elizabeth Hospital. As he reminded listeners, the current ASCO...
Bispecific Anti-CD20/Anti-CD19 CAR T Cells for Patients With Relapsed B-Cell Malignancies
In a single-institution phase I dose-escalation and -expansion trial reported as a letter in Nature Medicine, Shah et al found that treatment with tandem bispecific anti-CD20/anti-CD19 4-1BB–CD3ζ lentiviral (LV20.19) chimeric antigen receptor (CAR) T cells produced high response rates in adult...
Selpercatinib Shows Activity in RET Fusion–Positive NSCLC and RET-Altered Thyroid Cancer
As reported inThe New England Journal of Medicine by Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues and by Lori J. Wirth, MD, of Massachusetts General Hospital, and colleagues, the phase I/II LIBRETTO-001 trial has shown marked activity of the RET kinase ...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Chile
Chile has a population of approximately 19 million living predominantly in urban areas (87.7%), with a population density of 66 inhabitants per square mile.1 For the year 2020, approximately 12% of its population was older than 65 years.1 Socioeconomic Trends and Cancer The country has experienced ...
Daniel G. Petereit, MD, on Disparities in Lung Cancer Care for Northern Plains American Indians
Daniel G. Petereit, MD, of the John T. Vucurevich Cancer Care Institute and Monument Health, discusses the Walking Forward health-care program designed for a South Dakota–based Native American population, whose members have high smoking and death rates from lung cancer as well as limited access to...
An Integrated Framework for Improving Outcomes in Pancreatic Cancer
Drawing on several lines of ongoing research, David A. Tuveson, MD, PhD, has created a theoretical framework to consider while developing clinical trials in pancreatic cancer. In his keynote lecture at the 2020 American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer, ...
Checkpoint Inhibitor and Chemotherapy Combinations Fail to Move Bar as First-Line Therapy for Advanced Urothelial Cancer
Two different phase III studies found that combining an anti–PD-1/PD-L1 checkpoint inhibitor (pembrolizumab in KEYNOTE-361) with platinum-based chemotherapy or with another checkpoint inhibitor (the anti–CTLA-4 antibody tremelimumab in DANUBE) failed to significantly improve overall or...
Response-Based Management of Nivolumab and Ipilimumab Therapy in Metastatic Renal Cell Carcinoma
In the phase II OMNIVORE study reported in the Journal of Clinical Oncology, Rana R. McKay, MD, and colleagues did not find evidence supporting a strategy of discontinuing nivolumab monotherapy in responders and adding ipilimumab in nivolumab nonresponders among patients with metastatic renal cell...
Jeff M. Michalski, MD, MBA, on Medulloblastoma and Radiation Treatment in Pediatric Patients
Jeff M. Michalski, MD, MBA, of the Washington University School of Medicine, discusses a Children’s Oncology Group study that confirmed data previously reported: Involved-field radiotherapy is noninferior to posterior fossa radiotherapy in patients with average risk-medulloblastoma. However,...
Justin Oh, MD, on Prostate Cancer: Brachytherapy vs External-Beam Radiation Therapy
Justin Oh, MD, of the University of British Columbia, discusses results from the ASCENDE-RT trial, which compared a low-dose–rate brachytherapy boost to a dose-escalated external-beam boost for patients with high- and intermediate-risk prostate cancers (Abstract 127).
Study Finds Distinct Genomic Alterations May Contribute to More Aggressive Prostate Cancer in Black Men
A study by Liu et al published in Molecular Cancer Research investigated why Black men appear to be more likely to develop aggressive prostate cancer than White men. Researchers found that prostate tumors in Black men had higher frequencies of distinct genetic alterations, which may contribute to...
Are Neighborhood Poverty, Public Insurance Linked to Poorer Outcomes in Children With Cancer Undergoing Stem Cell Transplant?
Despite the increasing use of hematopoietic stem cell transplant as curative therapy for children with cancer and other life-threatening diseases, new research suggests that children who undergo a transplant for cancer may be more likely to die of treatment-related complications if they live in...
Prediagnosis and Postdiagnosis Physical Activity and Survival in Endometrial Cancer
In a Canadian study reported in the Journal of Clinical Oncology, Friedenreich et al found that postdiagnosis recreational physical activity was associated with significantly improved disease-free and overall survival among women with invasive endometrial cancer. Study Details The prospective...
Gemcitabine and Daily Radiation for Patients With Muscle-Invasive Bladder Cancer
Bladder preservation with trimodality therapy may be a safe and effective alternative to cystectomy for selected patients with muscle-invasive bladder cancer, according to results from a phase II trial presented by Coen et al at the virtual 2020 American Society for Radiation Oncology (ASTRO)...
Time at Home vs in Health-Care Institutions for Older Patients After Cancer Surgery
In a Canadian population-based cohort study reported in JAMA Surgery, Chesney et al found that older patients undergoing surgery for cancer were likely to spend a high number of days at home vs in health-care institutions in the years following surgery for cancer, suggesting favorable functional...
New Maintenance Therapies in Metastatic Pancreatic Cancer Aim to End Perpetual Chemotherapy
The advent of effective combination chemotherapies has changed the treatment landscape for metastatic pancreatic cancer, extending median survival and leading to durable responses in a subset of patients. However, perpetual chemotherapy is cumulatively toxic, leading to progressive bone marrow...
Pretreatment ctDNA May Help Predict Outcomes With First-Line—but Not Second-Line—Immunotherapy for Patients With Melanoma
A study by Marsavela et al published in Clinical Cancer Research evaluating the predictive value of pretreatment circulating tumor DNA (ctDNA) to inform therapeutic outcomes in patients with advanced-stage melanoma relative to type and line of treatment has found that baseline levels of ctDNA...
SBRT May Provide Superior Pain Relief From Spinal Metastases vs Conventional Radiotherapy
Stereotactic body radiation therapy (SBRT) was superior to conventional radiation therapy in reducing pain from spinal metastases in a phase II/III study reported by Arjun Sahgal, MD, and colleagues at the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract LBA 2). More...
Targeted Inhibitor of Mutant KRAS Gene Shows Activity in Early Trial
Adagrasib (MRTX849), a novel agent that targets a mutated form of the KRAS gene—the most commonly altered oncogene in human cancers, and one long considered “undruggable”—caused tumor shrinkage in most patients in a clinical trial, with manageable side effects, researchers reported at the 32nd...
Survey Shows Many Patients With Cancer Willing to Take Part in Clinical Trials Despite Coronavirus
Patient Power, a patient-driven cancer news organization, reported that a majority of patients with cancer still want to participate in clinical trials despite the COVID-19 pandemic, according to a recent survey of 1,485 patients. The Patient Power COVID-19 Cancer Trial Survey, the second Patient...
Expect Questions About Increased Cancer Mortality Risk Among Patients Diagnosed With DCIS
A large cohort study1 finding that the risk of dying of breast cancer was increased threefold after a DCIS diagnosis may cause patients diagnosed with DCIS to ask what they can do to reduce that risk. Currently, there is little that most patients can do. “The lifetime risk of death following DCIS...
Breaking Social Barriers to Conquer Cancer
Kala Visvanathan, MD, MHS, is working to prevent cancer in every patient. With the help of donor-supported grants, including a Career Development Award from Conquer Cancer®, the ASCO Foundation, Dr. Visvanathan researches cancer prevention and strategies to prevent cancer recurrence. “To be...
Focus on Preventing Invasive Recurrence in Women With DCIS Does Not Sufficiently Address Breast Cancer Mortality
A study published recently by Giannakeas et al looked at the risk of death from breast cancer for women diagnosed with ductal carcinoma in situ (DCIS).1 The investigators anticipated that treatment would eliminate the risk of invasive ipsilateral recurrence and prevent subsequent mortality from...
Preliminary Progress with Genetically Engineered T Cells in Treating Childhood ALL
Two small phase I studies at separate centers demonstrated encouraging results in the treatment of children with acute lymphoblastic leukemia (ALL) using reinfused autologous genetically engineered T cells. Results of both studies were presented at the Annual Meeting of the American Association for ...
The Gut, Our Choices, and Gynecologic Cancers: Investigating an Unlikely Trio
Disturbance of the gut microbial metabolism is thought to be the root cause of human diseases. Bacteria, viruses, and fungi affect their human hosts in numerous ways. There is evidence to support the theory that microbes, through their genetic makeup, gene products, and metabolites, play a role in...
Expert Point of View: Salah-Eddin Al-Batran, MD
Salah-Eddin Al-Batran, MD, Director of the Institute of Clinical Cancer Research and Director of GI Oncology at Krankenhaus Nordwest-University Cancer Center, Frankfurt, Germany, commented on KEYNOTE-590 at a press briefing. Dr. Al-Batran noted that the prognosis for advanced esophageal cancer is...
Dana-Farber/Harvard Cancer Center Wins Federal Grant to Accelerate Ovarian Cancer Research
Dana-Farber/Harvard Cancer Center (DF/HCC) has been awarded a $12 million grant from the National Cancer Institute (NCI) to bring promising ovarian cancer research from the laboratory to clinical practice. The highly competitive Specialized Programs of Research Excellence (SPORE) grant will help...
Panel With Diverse Perspectives Explores Strategies to Reduce Costs for Cancer Care
“Imagine that it’s 5 years from now, and we are in a situation where the cost of cancer care has flattened, and costs are even going down,” said Clifford Goodman, PhD, a Senior Vice President at the Lewin Group, turning to a panel of oncology and policy experts at his side. “What policies got us...
Surgical and Radiation Oncology in Elderly Patients With Cancer
As one might expect, the focus on older patients developed in surgical and radiation oncology at the same time as in medical oncology. As we have done in our overview of medical oncology, we may recognize a prehistory, past history, and present history in surgical and radiation geriatric oncology....
UICC Launches New Program at the Start of Breast Cancer Awareness Month
As the cancer community marks Breast Cancer Awareness Month this October, the Union for International Cancer Control (UICC) is starting a new 5-year program aimed at accelerating progress in breast cancer control. “While the incidence of breast cancer is generally higher in more developed regions, ...
Capmatinib Active in Advanced NSCLC With MET Exon 14 Skipping Mutations
As reported inThe New England Journal of Medicine by Jürgen Wolf, MD, of the Center for Integrated Oncology, University Hospital Cologne and University of Cologne, and colleagues, the phase II GEOMETRY mono-1 trial has shown durable responses with the selective MET inhibitor capmatinib in patients...
Early-Phase Study Reports Progress in Targeting KRAS-Mutated Tumors With Sotorasib
Although KRAS is one of the most frequently mutated oncogenes in human cancers, an almost 4-decade long search for drugs that hit this target has been elusive—until now. Sotorasib (formerly called AMG-510), a small-molecule inhibitor of the KRAS G12C mutation, demonstrated clinical activity and...
Expert Point of View: Fatima Cardoso, MD
The encouraging results of the phase III ASCENT trial suggest that sacituzumab govitecan has clearly earned a place in the treatment algorithm for advanced triple-negative breast cancer, said the study’s invited discussant, Fatima Cardoso, MD, Director of the Breast Unit at the Champalimaud...
FDA Pipeline: Priority Reviews in EGFR-Mutant Lung Cancer, Advanced Renal Cell Carcinoma; Fast Track Designations in CLL and Solid Tumors
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for EGFR-mutant lung cancer and advanced renal cell carcinoma; granted Fast Track designation to agents in chronic lymphocytic leukemia (CLL) and locally advanced or metastatic solid tumors; and more....
Adjuvant vs Salvage Radiotherapy Plus Short-Term ADT After Radical Prostatectomy for Localized Prostate Cancer
As reported in The Lancet Oncology by Sargos et al, the French phase III GETUG-AFU 17 trial has shown no event-free survival benefit for adjuvant radiotherapy vs salvage radiotherapy—both with short-term androgen-deprivation therapy (ADT)—after radical prostatectomy in men with localized prostate...
FDA Approves Remdesivir for Patients With COVID-19 Requiring Hospitalization
On October 22, the U.S. Food and Drug Administration (FDA) approved the antiviral drug remdesivir (Veklury) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kg for the treatment of COVID-19 requiring hospitalization. Remdesivir should only be administered...
ASTRO Issues Clinical Guideline on Radiation Therapy for Rectal Cancer
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance for physicians who use radiation therapy to treat patients with locally advanced rectal cancer. Recommendations outline indications and best practices for pelvic radiation treatments, as well as the...
ASCO Approves First Joint MSTS/ASTRO/ASCO Guideline on Treatment of Metastatic Carcinoma and Myeloma of the Femur
On June 20, 2020, ASCO approved the first joint Musculoskeletal Tumor Society (MSTS)/American Society for Radiation Oncology (ASTRO)/ASCO guideline on the care of patients with metastatic carcinoma and myeloma of the femur.1 Guideline recommendations were based on a systematic review of clinical...
